1-3 of 3
John Redman, MD
Close
Sort by
Journal Articles

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Timothy Burn, PhD, Kris Vaddi, PhD, DVM, John Redman, MD, Edward C Bradley, MD, Richard Levy, MD, Steven Friedman, MD, Gregory Hollis, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 2802.
https://doi.org/10.1182/blood.V112.11.2802.2802
Published: 2008
Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 1760.
https://doi.org/10.1182/blood.V112.11.1760.1760
Published: 2008
Journal Articles

INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, MD, Animesh Pardanani, MD, PhD, Deborah Thomas, MD, Jorge Cortes, MD, Ruben Mesa, MD, John Redman, MD, Carl-Michael Staschen, MD, PhD, Jordan Fridman, PhD, Kris Vaddi, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2007) 110 (11): 558.
https://doi.org/10.1182/blood.V110.11.558.558
Published: 2007